Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 17/20 | 0.68 |
| ▸ | SSTR5 | P35346 | 16/20 | 0.68 |
| ▸ | SSTR3 | P32745 | 7/20 | 0.65 |
| ▸ | SSTR1 | P30872 | 4/20 | 0.65 |
| ▸ | SSTR4 | P31391 | 9/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18872540 | 1.00 | SSTR2 (0.68) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL31632623 | 0.91 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL30163296 | 0.91 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL6369050 | 0.91 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL4827 | 0.91 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL29405608 | 0.91 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL4826 | 0.91 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL294911 | 0.90 | SSTR2 (0.80) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL29384009 | 0.90 | SSTR2 (0.80) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL29580907 | 0.90 | SSTR2 (0.80) | SSTR2SSTR5SSTR3SSTR1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137443-A1 | BORON-BASED PRODRUG STRATEGY FOR INCREASED BIOAVAILABILITY AND LOWER-DOSAGE REQUIREMENTS FOR DRUG MOLECULES CONTAINING AT LEAST ONE PHENOL (OR AROMATIC HYDROXYL) GROUP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137443-A1 | BORON-BASED PRODRUG STRATEGY FOR INCREASED BIOAVAILABILITY AND LOWER-DOSAGE REQUIREMENTS FOR DRUG MOLECULES CONTAINING AT LEAST ONE PHENOL (OR AROMATIC HYDROXYL) GROUP | ABCB1, CYP2B6, PAH | SSTR2 834/4885SSTR5 1104/4885SSTR3 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.